Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
IPO Year: 1992
Exchange: NASDAQ
Website: orthofix.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
10/20/2023 | $12.00 | Neutral | ROTH MKM |
9/12/2023 | Buy → Neutral | BTIG Research | |
9/12/2023 | Buy → Hold | Stifel | |
7/19/2023 | $27.00 | Buy | BTIG Research |
3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
4 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
SD - Orthofix Medical Inc. (0000884624) (Filer)
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on
Company to Host Conference Call on Tuesday, August 6, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Recent Highlights Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 16%, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on a reported basis, primarily driven by U.S. Orthopedic net sales growth of 23% First quarter 2024 net loss of $36 million; Non-GAAP Adjusted EBITDA of $8 million, an increase of $4.5 million, a 220 basis point expansion over prior year Midpoint of full
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and
Recent Highlights Fourth quarter 2023 net sales of $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis Bone Growth Therapies net sales growth of 15% for the fourth quarter of 2023, marking four consecutive quarters with double-digit net sales increases, representing the strongest quarter of Bone Growth Therapies sales in the history of Orthofix U.S. Orthopedic net sales growth of 11% for the full year 2023 U.S. spine fixation1 net sales growth of 13.5% in Q4 2023 with net distributor additions since the third quarter of 2023 Fourth quarter 2023 net loss of $22 million; Non-GAAP Adjusted EBITDA of $20 million, or 10% of sales, r
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the co
In November 2023, entered into a new four-year financing agreement with borrowing capacity of up to $150 million Net sales of $184.0 million, an increase of 61% on a reported basis and an increase of 8% on a pro forma basis when normalizing for a one-time stocking order that occurred in the third quarter of 2022 for SeaSpine Bone Growth Therapies growth of 15%, marking three consecutive quarters with double-digit net sales increases, with growth coming from both spine and fracture portfolios U.S. spinal implants, biologics, and enabling technologies sales growth of 7% on a pro forma basis over prior year Global Orthopedics net sales increase of 7% on a reported basis over prior
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference c
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call
Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year Bone Growth Therapies growth of 14%, with growth coming from both spine and fracture commercial channels U.S. spinal implant sales up 18% over prior year on a pro forma basis, driven by new distribution and product innovation Continued double-digit growth in Global Orthopedics over prior year on a constant currency basis Announced the full commercial launch of the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, which addresses an estimated $1.8 billion market related to minimally invasive spine procedures Orthofix Me
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on
Wednesday, August 14, 2024 at 2:30 pm Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the Company will participate in Canaccord Genuity's 44th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 14, 2024 at 2:30 pm ET. Interested parties can access the live and archived webcast of the presentation on the Investors section of the Orthofix website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.orthofix.com. The Company encourages investors and
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the 510(k) clearance and first U.S. implant of the Fitbone™ Transport and Lengthening System. Used to treat large bone defects in the femur and tibia due to trauma, infectious or malignant conditions, the device is the only intramedullary nail designed to transport or lengthen the bone through a single surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709682923/en/The Fitbone™ Transport and Lengthening System, used to treat large bone defects in the femur and tibia due to trauma, infectious or malignant conditions, is th
Company to Host Conference Call on Tuesday, August 6, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Finegan was appointed to the Orthofix Board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing a portfolio of fully engineered synthetic materials for soft tissue repair and regenerative medicine. Prior to joining Acera, Finegan spent 14 years at Orthofix where he served
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company's operations, manufacturing, regulatory, clinical, and quality teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618902092/en/Aviva McPherron, President of Global Operations and Quality at Orthofix Medical Inc. (Photo: Business Wire) McPherron joins Orthofix from Globus Medical where she served as Senior Vice President, Clinical Services and Integrat
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company's global spine business. Dewey and Reinhardt will serve on Orthofix's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611316728/en/Julie Dewey, Chief Investor Relations and Communications Officer, Orthofix Medical Inc. (Photo: Business Wire) A seasoned investor relations and communications executive, Dewey previously held roles a
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company's global spine and biologics business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523192754/en/Max Reinhardt, incoming President of the Orthofix Global Spine business. (Photo: Business Wire) Reinhardt's experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
ROTH MKM initiated coverage of Orthofix with a rating of Neutral and set a new price target of $12.00
BTIG Research downgraded Orthofix from Buy to Neutral
Stifel downgraded Orthofix from Buy to Hold
BTIG Research resumed coverage of Orthofix with a rating of Buy and set a new price target of $27.00
Stifel upgraded Orthofix Medical from Hold to Buy and set a new price target of $45.00 from $41.00 previously
The Rodeo Telescopic Nail is a device indicated to surgically treat deformities or fractures in patients suffering from osteogenesis imperfecta (OI). The nail implant serves to stabilize the patient's limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for ZoomInfo Technologies Inc. (NASDAQ:ZI) from $24 to $15. Piper Sandler analyst Brent Bracelin downgraded the stock from Overweight to Neutral. ZoomInfo Technologies shares fell 3.6% to close at $16.02 on Tuesday. See how other analysts view this stock. Baird boosted the price target for Datadog, Inc. (NASDAQ:DDOG) from $130 to $140. Baird analyst William Power upgraded the stock from Neutral to Outperform. Datadog shares fell 11.5% to close at $112.40 on Tuesda
Roth MKM analyst Jason Wittes upgrades Orthofix Medical (NASDAQ:OFIX) from Neutral to Buy and raises the price target from $15 to $20.
Orthofix Medical (NASDAQ:OFIX) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.33) by 187.88 percent. This is a 850 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $188.60 million which beat the analyst consensus estimate of $184.13 million by 2.43 percent. This is a 7.65 percent increase over sales of $175.20 million the same period last year.
JMP Securities analyst David Turkaly reiterates Orthofix Medical (NASDAQ:OFIX) with a Market Perform.
Roth MKM analyst Jason Wittes maintains Orthofix Medical (NASDAQ:OFIX) with a Neutral and raises the price target from $12 to $15.
Orthofix Medical (NASDAQ:OFIX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.08) by 637.5 percent. This is a 68.57 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $200.41 million which beat the analyst consensus estimate of $195.31 million by 2.61 percent. This is a 63.97 percent increase over sales of $122.23 million the same period last year.
Non-GAAP adjusted EBITDA of $62 million to $67 million, representing a $15.7 million to $20.7 million increase, over the full year 2023
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Finegan was appointed to the Orthofix Board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing a portfolio of fully engineered synthetic materials for soft tissue repair and regenerative medicine. Prior to joining Acera, Finegan spent 14 years at Orthofix where he served
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company's operations, manufacturing, regulatory, clinical, and quality teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618902092/en/Aviva McPherron, President of Global Operations and Quality at Orthofix Medical Inc. (Photo: Business Wire) McPherron joins Orthofix from Globus Medical where she served as Senior Vice President, Clinical Services and Integrat
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company's global spine business. Dewey and Reinhardt will serve on Orthofix's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611316728/en/Julie Dewey, Chief Investor Relations and Communications Officer, Orthofix Medical Inc. (Photo: Business Wire) A seasoned investor relations and communications executive, Dewey previously held roles a
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company's global spine and biologics business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523192754/en/Max Reinhardt, incoming President of the Orthofix Global Spine business. (Photo: Business Wire) Reinhardt's experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821173/en/Andres Cedron, Chief Legal Officer for Orthofix (Photo: Business Wire) Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Cedron oversaw Stryker's corporate governance, SEC compliance, mergers and acquisitions, and ESG matters. "With a broad breadth of experience in the medical device i
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1. A seasoned sales leader, Shallenberger previously served as Vice President of U.S. Sales and Marketing for the Orthofix Bone Growth Therapies business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229167353/en/Orthofix names Jason Shallenberger as President, Bone Growth Therapies (Photo: Business Wire) Prior to this realignment, the Bone Growth Therapies business was ma
Massimo Calafiore begins as President and Chief Executive Officer, effective immediately Julie Andrews is appointed as Chief Financial Officer, assuming the role effective January 15, 2024 Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that effective immediately, Massimo Calafiore has assumed the role of President and Chief Executive Officer (CEO) and as a member of the Orthofix Board of Directors. In conjunction with Mr. Calafiore stepping into his role as CEO, the Company has announced the appointment of Julie Andrews as Chief Financial Officer. Ms. Andrews previously served as CFO for Smart Wires Technology, where she led all f
Three New Directors Bring Substantial Finance, Strategic Development, Healthcare and MedTech Experience Orthofix Medical Inc. (NASDAQ:OFIX) ("Orthofix" or the "Company") today announced the appointment of three new independent directors to the Company's Board. These new directors bring substantial finance, strategic development, healthcare and medical technology experience to further advance Orthofix's position as a leading global spine and orthopedics company. The appointments follow constructive engagement and entry into a cooperation agreement with Engine Capital Management, LP (together with its affiliates, "Engine"), one of the Company's largest shareholders, which owns approximately